Pieris Pharmaceuticals plans to start clinical development of PRS-220 in 2022 for idiopathic pulmonary fibrosis (IPF) — and also will advance the investigative, inhaled therapy for “long COVID” PF, or post-COVID-19 pulmonary fibrosis, the company said. The clinical development of PRS-220 for long COVID pulmonary fibrosis will be…
Inhaled PRS-220 Aims to Treat Both IPF and ‘Long COVID’ PF
The acid reflux medication esopremazole, commonly used to ease symptoms of gastroesophageal reflux disease (GERD), may be able to reduce lung scarring and inflammation in idiopathic pulmonary fibrosis (IPF), a recent study suggests. “Esomeprazole favorably regulates a network of genes involved in lung fibrosis [scarring],” according…
I love the memories feature offered on various social media platforms. With the click of a button, you can revisit what you were doing or posting about on the same day in previous years. I recently read an old post on one of my social media pages that reminded…
A computer analysis identified a tiny RNA molecule, or microRNA, as a potential therapeutic target to halt the progression of idiopathic pulmonary fibrosis (IPF), which was confirmed later in cell-based tests. Researchers now plan to use these results to develop new RNA-based therapeutics or small molecules with the potential…
To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…
I had an epiphany last week: It’s hard to find a job! My first thought was that it must be my age. My experience doesn’t matter because I don’t fit into the work culture. (I’d never heard of “work culture” until I saw it on LinkedIn.) My second…
A radioactive molecule that can be seen on positron emission tomography (PET) scans may offer a non-invasive way to identify and monitor pulmonary fibrosis (PF), a study in mice reported. Further development of this radiotracer — which binds to activated fibroblasts in the lungs — could support its…
Thirona Bio has teamed with MannKind Corporation to develop and test a potential inhaled treatment for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). FBM5712, which Thirona is working to advance as a possible topical treatment of skin fibrosis, will be modified and investigated by MannKind for its…
The U.S. Food and Drug Administration (FDA) has accepted United Therapeutics’ application for a priority review of Tyvaso DPI, an experimental dry powder inhaled formulation of treprostinil, to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). …
Following my idiopathic pulmonary fibrosis (IPF) diagnosis in 2016, I had many fears. As an avid traveler, my No. 1 fear was being put on supplemental oxygen and losing the ability to fly. I also feared that using oxygen would prevent me from partaking in many of the outdoor…
